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Background: Current optimal evidence based treatment of patients presenting for primary percutaneous coronary intervention (PPCI) includes 
the use of manual thrombus aspiration (TA) catheters and/or glycoprotein IIb/IIIa inhibitors (GPI). These therapies have been shown in randomised 
controlled trials to reduce mortality and limit final infarct size. However real world data is lacking and trial outcomes in selected patient populations 
may fail to translate into practise. Our study aimed examined outcome by treatment group; TA alone (TA), GPI alone (GA), both TA/GPI (TAG) or 
neither TA/GPI (NTG).
Methods: Consecutive patients attending two UK centres undergoing PPCI for STEMI between September 2008 and December 2010 were included 
in the analysis (n=1,656). All patients were preloaded with 600mg clopidogrel and 300mg aspirin prior to their procedure. Interventional strategy 
and adjuvant pharmacology use was left to the discretion of the operator. Patient data and outcome measurements were obtained by interrogation 
of notes and through national databases.
Results: 1,656 patients (mean age 65.3±12.5years, 75.1% male) were included in the analysis with an overall mortality rate of 8.8% at one 
year. Each group was composed as follows: TA (n=343), GA (n=235), TAG (n=704) and NTG (n=374). Patients in the NTG group were older (mean 
age 68.6yrs±13.2, p<0.01) but other baseline demographics were similar across groups, including diabetes mellitus (p=0.65), cardiogenic shock 
(p=0.60) and pain to device time (p=0.18). 1-year mortality by group was 10.6% (TA), 7.8% (GA), 7.0% (TAG) and 11.3% (NTG)(p=0.129). The use 
of TA did not reduce mortality (8.2% vs 9.9%, p=0.29), however use of GPI resulted in a significant reduction in mortality at 1 year (7.2% vs 11.0%, 
p=0.02).
Conclusions: In an unselected population undergoing PPCI for STEMI, only patients who received GPI had a reduction in mortality at one year. 
Additionally these results demonstrate that unselected TA use confers no survival advantage. Further studies are required to ascertain the utility of a 
more targeted strategy for manual thrombectomy devices.
